ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.700
-0.090 (-3.23%)
Jun 27, 2025, 4:00 PM - Market closed
ImmunityBio Employees
ImmunityBio had 680 employees as of December 31, 2024. The number of employees increased by 52 or 8.28% compared to the previous year.
Employees
680
Change (1Y)
52
Growth (1Y)
8.28%
Revenue / Employee
$45,915
Profits / Employee
-$601,619
Market Cap
2.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IBRX News
- 16 days ago - ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze - Seeking Alpha
- 25 days ago - ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Business Wire
- 26 days ago - ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Business Wire
- 4 weeks ago - ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - Business Wire
- 6 weeks ago - ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code - Business Wire
- 7 weeks ago - ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA - Seeking Alpha
- 7 weeks ago - ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
- 7 weeks ago - ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 - Business Wire